SCHEDULE 13D/A: Neil Desai's Stake in Aadi Bioscience Drops Below 5% Following Major PIPE Financing
Beneficial Ownership Update
Neil Desai's beneficial ownership in Aadi Bioscience, Inc. has fallen to 4.9% after the company completed a private placement (PIPE) financing, issuing 21.6 million new shares.
Summary
- Neil Desai's beneficial ownership in Aadi Bioscience, Inc. has decreased to 4.9% of the common stock.
- This change is a direct result of Aadi Bioscience, Inc. issuing and selling 21,592,000 shares of common stock in a private placement (PIPE Financing).
- The PIPE Financing was previously disclosed on December 19, 2024, and received stockholder approval on February 28, 2025.
- As of March 4, 2025, Dr. Desai beneficially owns an aggregate of 2,272,941 shares, comprising 461,700 shares from exercisable options and 1,811,241 shares held through trusts.
- The total outstanding shares of Common Stock as of March 4, 2025, were 46,294,912, excluding Dr. Desai's options for the base calculation.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of a change in beneficial ownership due to a completed PIPE financing. While the financing itself is positive for the company's capital position, it results in dilution for existing shareholders, including the reporting person. The overall sentiment is neutral to slightly positive, reflecting the successful capital raise.
Positives
- The completion of a private placement (PIPE) financing, which raised capital for Aadi Bioscience, Inc., indicates successful funding for the company's operations.
Negatives
- Neil Desai's beneficial ownership percentage in Aadi Bioscience, Inc. decreased from over 5% to 4.9%, indicating dilution for existing shareholders due to the issuance of new shares in the PIPE financing.
Future Outlook
The document does not contain explicit forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing is a standard disclosure of a change in beneficial ownership following a significant capital raise by the company. It does not provide sufficient information to analyze broader industry trends or competitive positioning.
Stakeholder Impact
- Shareholders: Existing shareholders experienced dilution due to the issuance of 21,592,000 new shares in the PIPE financing, which reduced their proportional ownership.
- Company (Aadi Bioscience, Inc.): The company benefited from the capital raised through the PIPE financing, providing funds for operations and strategic initiatives.
Key Dates
| Date | Description |
|---|---|
| 2021-09-08 | Initial Statement of Beneficial Ownership on Schedule 13D filed by Neil Desai. |
| 2023-01-17 | Amendment No. 1 to Schedule 13D filed. |
| 2024-10-01 | Amendment No. 2 to Schedule 13D filed. |
| 2024-12-19 | Date of previous disclosure regarding the PIPE Financing. |
| 2024-12-23 | Amendment No. 3 to Schedule 13D filed. |
| 2025-02-28 | Date when the Issuer's stockholders approved the PIPE Financing at a special meeting. |
| 2025-03-04 | Date of event which required filing of this statement; Issuer issued and sold 21,592,000 shares in the PIPE Financing, leading to Dr. Desai ceasing to be a beneficial owner of more than five percent. |
| 2025-03-06 | Date of signature for this Amendment No. 4. |
Keywords
Aadi Bioscience, Neil Desai, Schedule 13D, Beneficial Ownership, PIPE Financing, Common Stock, SEC Filing, Share Dilution, Private Placement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.